Managing EGFR Inhibitor Induced Rash

Rash occurs in approximately 90% of patients treated with epidermal growth factor receptor (EGFR) inhibitors1 with 10-20% developing severe eruption. 1 Studies have shown that the presence of this rash is indicative of response to treatment. 1 Therefore, it is important to prevent and manage this side effect appropriately in an effort to avoid holding or decreasing the dose of EGFR inhibitors.